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avoided ORT and CVE, from the public perspective in Brazil, with associated in-
crease costs.
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OBJECTIVES: Blood stem cell mobilization, which is important as a source of he-
matopoietic stem cells for transplantation, is performed using granulocyte colony-
stimulating factor (G-CSF), but is ineffective in around 20% of so called poor mobi-
lizers. Combining G-CSF with plerixafor increases the percentage of successful
mobilizations. The drug has orphan drug status and is approved for lymphoma and
multiple myeloma patients. The objective was to compare the cost-effectiveness of
three available mobilization schemes: i) the use of plerixafor “on demand” (POD)
even during a first mobilization attempt in all patients who show inadequate re-
sponse, ii) the standard use of Plerixafor strictly within a standard re-mobilization
scheme following failure of the first mobilization (SSP), and iii) the standard (re-
)mobilization scheme without Plerixafor (SSNP). METHODS: Decision tree models
were built to compare clinical outcomes and direct costs from the payer’s perspec-
tive in all three strategies. They were populated with efficacy resource use data
from a first-of-a-kind patient registry of all patients with plerixafor administered
(n93) in 6 Czech centres. RESULTS: The success rates and costs for POD, SSP and
SSNP were 94.9% and EUR 5,736, 94.7% and EUR 6,416, and 84.7% and EUR 4,775,
respectively. The direct cost per successfully treated average patient was EUR
6,046, EUR 6,776 and EUR 5,641, respectively. The cost of the first mobilization
attempt with G-CSF was EUR 3,905 per patient. The cost of re-mobilization of a poor
mobilizer was EUR 4,629 with G-CSF only and EUR 13,354 if plerixafor was added.
The total cost of plerixafor used on-demand in the sub-cohort of poor mobilisers
was EUR 13,645. CONCLUSIONS: Plerixafor substantially increases chances of suc-
cess and its use is more cost-effective “on demand” during early mobilization than
in subsequent re-mobilization.
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OBJECTIVES: To evaluate the cost-effectiveness of icatibant [Shire HGT] 30 mg
subcutaneous versus C1-esterase inhibitor concentrate (C1-INH) [CSL-Behring] 20
IU/kg intravenous for moderate to severe attacks of hereditary angioedema (HAE)
types I and II in the UK setting. METHODS: A probabilistic cost-utility model was
developed over a time horizon of 96 h (the duration of a single acute attack). Com-
parisons were made for therapy administered at home and in hospital. Quality-
adjusted life years (QALYs) were estimated by combining the time to onset of
symptom relief with utility weights for the health states before and after onset of
symptom relief. Clinical evidence and other model parameters were identified by
systematic review. An indirect comparison using previously published methods
was conducted. Costs relating to drug acquisition; administration; repeat injec-
tions; monitoring and supportive care; hepatitis A and B vaccinations for C1-INH;
self-administration training; and adverse events were considered. Probabilistic
and univariate sensitivity analyses were conducted. RESULTS: The indirect analy-
sis suggested a non-significant trend towards a reduced time to symptom relief for
icatibant when compared with C1-INH. In the economic analysis, there was a non-
significant inter-treatment difference in estimated QALYs per attack, equivalent to
0.75 quality-adjusted life hours in icatibant’s favour. In the base-case analysis
(SmPC dosing and NHS list price), total costs per attack were estimated as £1,577 for
icatibant and £2,169 for C1-INH; a saving of £592 (95%CI: £394–£715) per attack with
icatibant. CONCLUSIONS: This is one of the first comparative health economic
models presented for HAE. The systematic approach to data identification and
analysis led to successful submissions to SMC and AWMSG in this orphan indica-
tion. The analysis demonstrated that icatibant reduces costs versus C1-INH (20
IU/kg at SmPC dosing) when treating acute HAE attacks in the UK setting.
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OBJECTIVES: To estimate the cost-effectiveness of febuxostat compared with allo-
purinol in the treatment of hyperuricaemia in patients with chronic gout when
urate deposition has already occurred. METHODS: A Markov model was developed
to estimate costs, clinical outcomes, and QALYs for patients with hyperuricaemia
and chronic gout. Febuxostat 80 mg/120 mg as first line therapy (with or without
allopurinol as second line therapy) and as second line therapy (after first line allo-
purinol) was compared to current standard therapy, i.e. allopurinol 300 mg daily
with no second line treatment. A dichotomous sUA response/no response outcome
after the first 3 months of each active treatment was used to decide when patients
switched to a second line treatment. The definition of sUA response was applied
using a target sUA level of  6.0 mg/dL which was based on the latest EULAR
guidelines. Efficacy data (sUA levels) were derived from febuxostat Phase III trials
(APEX, FACT). Unit costs were derived from official tariffs (€2009). 3% discount rate
and 5-year time horizon was applied in the primary analysis. Sensitivity analyses
were performed to assess the impact of variations on all model inputs and sub-
group analyses (patients intolerant to allopurinol, or patients having mild-moder-
ate renal impairment). Analyse was carried out from the National Health System
perspective. RESULTS: The addition of febuxostat in any therapeutic strategy (both
as first-line or second line treatment) is an efficient option, with incremental cost-
effectiveness ratios (ICER) compared with standard allopurinol 300 mg ranging
from 3,800 € to 6,600 €. The cost-effectiveness results show that the two-step two-
drug treatment strategies provide additional QALY benefit over the single-step
single-drug treatment strategies. CONCLUSIONS: Results suggest that febuxostat
is a cost-effective treatment in Spain for the management of hyperuricemia in
patients with gout, showing ICERs far below the commonly cited efficiency thresh-
old in Spain (30,000€/QALY).
PSY29
TITLE: THE CHALLENGE OF CONDUCTING A PROSPECTIVE ECONOMIC
EVALUATION OF A PHARMACOGENETIC TEST
Thompson A1, Payne K1, Roberts SA1, Newman W2, Elliott RA3, Tricker K2
1University of Manchester, Manchester, UK, 2University of Manchester and Central Manchester
NHS Foundation Trust, Manchester, UK, 3University of Nottingham, Nottingham, UK
OBJECTIVES: A pharmacogenetic test (PGx) prior to prescribing azathioprine is
available to identify patients at increased risk of dose-limiting side effects (eg.
neutropaenia). This study had two aims (1) to evaluate whether the PGx is a cost
effective use of health care resources and (2) to understand whether it is feasible to
conduct a prospective economic trial of a PGx. METHODS: An economic evaluation
integrated into a prospective, pragmatic, multi-centre (n19) randomised con-
trolled trial (RCT) compared (i) PGx with standard care (SC); 167 patients to (ii) SC
comprising step-wise dose escalation of azathioprine; 166 patients. The perspec-
tive of the UK NHS, with 4-month time horizon, was used to be consistent with the
original RCT (the TARGET study). Individual patient-level data on resource use
(primary care, secondary care, drug-use, monitoring tests) and health status (EQ-
5D) were collected for all recruited patients. Quality adjusted life years (QALYs)
were calculated using UK-population EQ-5D tariffs. Unit costs were collected from
national sources (price year: 2010). GLM regression models estimated incremental
costs and QALYs. Uncertainty in the results was characterised through the use of
non-parametric bootstraps and cost-effectiveness acceptability curves with one-
way sensitivity analysis to explore methodological assumptions. RESULTS: PGx
with SC was £436 (95% CI: -£1064, £119) less expensive but with fewer QALYs
0.00451 (95% CI: -0.01291, 0.00430) compared with only SC. Analysis indicated that
clinicians did not follow azathioprine prescribing recommendations in the PGx
arm, resulting in no difference in the dosage of azathioprine between the two arms
at 4-months (p0.25). Uncertainty in the results was driven by problems associated
with prescribing behaviour as well as low power due to small sample size.
CONCLUSIONS: The analysis found that PGx could be a cost-effective use of re-
sources but key uncertainties remain, driven by the challenge of conducting a
trial-based economic evaluation of a diagnostic PGx.
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OBJECTIVES: To evaluate the cost-effectiveness of ustekinumab for the treatment
of moderate-to-severe plaque psoriasis from the perspective of the public health
care institutions in Mexico.METHODS:A Markov model was developed to simulate
patients with moderate-to-severe plaque psoriasis. Biologic therapies compared
were ustekinumab 45mg every 12 weeks, adalimumab 40mg every two weeks,
etanercept 50mg twice a week and infliximab 5mg/kg every eight weeks. Measured
by the Psoriasis Area and Severity Index (PASI), clinical response was derived from
the latest published meta-analysis. PASI response was translated into QALYs in
two steps: (1) defining the correlation between PASI levels and the Dermatology Life
Quality Index (DLQI); and (2) using a formula to predict utility from DLQI score
derived from a mapping exercise of the DLQI with the EQ-5D. The model considered
expenditure on drugs, monitoring visits, adverse events and inpatient stays. Costs
were obtained from Mexican public institutions. Health and economic outcomes
were estimated over a 10-year time horizon with cycle length of 12 weeks. Cost and
QALYs were discounted at 5% annually. RESULTS: For patients with body weigh
above 60kg, Adalimumab was an extended dominated strategy by ustekinumab.
For these patients, the incremental cost-per-QALY of ustekinumab vs etanercept
was US$19,542, whereas the incremental cost-per-QALY of infliximab vs usteki-
numab was US$87,745. For patients with body weigh below 60kg, infliximab is more
effective and less costly than adalimumab and ustekinumab, while the incremen-
tal cost-per-QALY vs etanercept was US$5,202. CONCLUSIONS: Considering the
GDP per-capita of Mexico in 2010 (US$9,123), and according to the WHO Commis-
sion on Macroeconomics and Health, in patients with body weigh above 60kg
ustekinumab is a cost-effective strategy (3xGDP per-capita /QALY gained); while
in patients with body weigh below 60kg infliximab is a highly cost-effective strat-
egy (1xGDP per-capita/QALY gained). Probabilistic sensitivity analysis results did
not change the conclusions.
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